

Associations Between Measures of Sarcopenic Obesity and Risk of Cardiovascular Disease and Mortality: A Cohort Study and Mendelian Randomization Analysis Using the UK Biobank

Ruth E. Farmer, PhD;* Rohini Mathur, PhD;* A. Floriaan Schmidt, PhD; Krishnan Bhaskaran, PhD; Ghazaleh Fatemifar, PhD; Sophie V. Eastwood, MSc, MBChB; Chris Finan, PhD; Spiros Denaxas, PhD; Liam Smeeth, FRCGP, PhD; Nish Chaturvedi, PhD

Background—The “healthy obese” hypothesis suggests the risks associated with excess adiposity are reduced in those with higher muscle quality (mass/strength). Alternative possibilities include loss of muscle quality as people become unwell (reverse causality) or unmeasured confounding.

Methods and Results—We conducted a cohort study using the UK Biobank (n=452 931). Baseline body mass index (BMI) was used to quantify adiposity and handgrip strength (HGS) used for muscle quality. Outcomes were fatal and non-fatal cardiovascular disease, and mortality. As a secondary analysis we used waist-hip-ratio or fat mass percentage instead of BMI, and skeletal muscle mass index instead of HGS. In a subsample, we used gene scores for BMI, waist-hip-ratio and HGS in a Mendelian randomization (MR). BMI defined obesity was associated with an increased risk of all outcomes (hazard ratio [HR] range 1.10–1.82). Low HGS was associated with increased risks of cardiovascular and all-cause mortality (HR range 1.39–1.72). HRs for the association between low HGS and cardiovascular disease events were smaller (HR range 1.05–1.09). There was no suggestion of an interaction between HGS and BMI to support the healthy obese hypothesis. Results using other adiposity metrics were similar. There was no evidence of an association between skeletal muscle mass index and any outcome. Factorial Mendelian randomization confirmed no evidence for an interaction. Low genetically predicted HGS was associated with an increased risk of mortality (HR range 1.08–1.19).

Conclusions—Our analyses do not support the healthy obese concept, with no evidence that the adverse effect of obesity on outcomes was reduced by improved muscle quality. Lower HGS was associated with increased risks of mortality in both observational and MR analyses, suggesting reverse causality may not be the sole explanation. (*J Am Heart Assoc.* 2019;8:e011638. DOI: 10.1161/JAHA.118.011638.)

Key Words: cardiovascular outcomes • epidemiology • grip strength • Mendelian randomization • obesity

The existence of a “healthy obese” phenotype, whereby a subgroup of individuals overcome the excess risk of cardiovascular disease (CVD) and overall mortality associated with obesity, remains debated. Proposed explanations for this paradox include: (1) a favorable metabolic profile, which has been widely studied¹; and (2) the co-occurrence of higher muscle mass or strength. Sarcopenia (the age-related loss of muscle mass and strength), is also associated with adverse outcomes.^{2–4} Whether the effects of sarcopenia and obesity

are cumulative, or whether an interaction exists is unclear. A recent review of prospective studies including 35 287 participants reported that individuals with both excess fat and sarcopenia (sarcopenic obesity) had a 24% higher risk of all-cause mortality compared with individuals with sarcopenia alone or obesity alone, though confidence limits were wide (95% CI 12%–37%).⁵ The optimal measure of sarcopenia (muscle mass versus muscle quality) for event prediction remains contested.⁶ The optimal choice of obesity measure,

From the Department of Non Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom (R.E.F., R.M., K.B., L.S.); Institute of Cardiovascular Science (A.F.S., S.V.E., N.C.) and The Institute of Computer Science (C.F.), University College London, United Kingdom; Division Heart and Lungs, Department of Cardiology, University Medical Center Utrecht, Netherlands (A.F.S.); The Farr Institute of Health Informatics, London, United Kingdom (G.F., C.F., S.D.); The Institute of Health Informatics, University College London, London, United Kingdom (G.F., S.D.).

Accompanying Tables S1 through S14 and Figures S1 through S6 are available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.118.011638>

*Dr Farmer and Dr Mathur contributed equally to this work.

Correspondence to: Ruth E. Farmer, PhD, Department of Non Communicable Diseases Epidemiology, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom. E-mail: ruth.farmer@lshtm.ac.uk

Received December 5, 2018; accepted April 23, 2019.

© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Clinical Perspective

What Is New?

- In a large sample of UK adults, greater muscle quality, quantified by both directly measured and genetically predicted hand-grip strength, was estimated to reduce cardiovascular and all-cause mortality risk.
- There was no evidence for “healthy obesity:” higher body mass index was associated with higher cardiovascular and all-cause mortality risk, and this was not attenuated in people with better muscle quality.

What Are the Clinical Implications?

- Grip strength may be a useful prognostic indicator for cardiovascular and all-cause mortality risk, regardless of adiposity level.

whether central, (such as waist-hip-ratio [WHR]), or general (specifically body mass index [BMI]) is also unclear.^{7–11} Concerns of reverse causality between obesity and outcomes, particularly mortality, remain. For example, excess mortality in those who have both lost weight and developed sarcopenia as a consequence of disease may drive the appearance of a protective effect of obesity.

We utilized UK Biobank (UKB) to determine the association between sarcopenia, obesity and their interaction with CVD events and mortality. We examined effect modification by pre-existing CVD and examined evidence for non-linearity of these associations. As a secondary aim, we investigated the impact of using different metrics for adiposity and muscle quality. Mendelian randomization (MR) was used as a further causal inference method to explore the relationship between genetic instruments (and their interactions) for obesity and sarcopenia and CVD outcomes. Under certain assumptions, given that genetic variation is determined at conception, such associations are robust to both confounding and reverse causation.¹²

Methods

Study Population

The data that support the findings of this study are available to verified researchers upon application to the UKB in accordance with their access procedures (<http://www.ukbiobank.ac.uk>). The UKB cohort^{13,14} recruited 502,641 men and women aged 40 and 69 years between 2006 and 2010 from primary care practices, spanning England, Scotland, and Wales. Participants underwent a baseline assessment capturing sociodemographic and lifestyle factors, and health status, including several measures of adiposity, muscle mass and muscle strength. Validated genotyping data were available

from the initial release of genetic data for a random sample of 150 000 participants. White European participants from this sample with both phenotype and genotyping data passing quality control were eligible for MR analysis. UKB genotyping and imputation documentation are available at <http://www.ukbiobank.ac.uk/scientists-3/genetic-data/>. Longitudinal follow-up for health-related outcomes and mortality was available for all participants via linked secondary care records and death registrations via the office for national statistics.

This study had local approval from the UKB (project number 21893) and institutional approval from the London School of Hygiene & Tropical Medicine (application 15770). All participants provided informed consent at the time of recruitment to the UKB.

Observed Phenotypes

Body mass index and grip strength

General obesity was defined using BMI, calculated with weight and height measurements taken at the baseline assessment. Muscle quality was defined as isometric handgrip strength (HGS), from the dominant hand using a Jamar dynamometer.^{15–17}

We created binary variables for presence or absence of obesity or sarcopenia. The BMI cut-off was $>30 \text{ kg/m}^2$. Sarcopenia was dichotomized using HGS cut-offs at $<30 \text{ kg}$ for men and $<20 \text{ kg}$ for women.¹⁸

A composite of 4 mutually exclusive categories of body composition was generated. These were “optimal body composition” (ie, non-obese and non-sarcopenic), “obese non-sarcopenic,” “sarcopenic non-obese,” and “sarcopenic obesity.”

We further categorized each continuous exposure into quintiles to examine non-linear associations between obesity and sarcopenia. The studied population equated to the following cut points: BMI: 23.55, 25.72, 27.85, and 30.82 kg/m^2 ; HGS: 22, 28, 34, and 42 kg.

Outcome Variables

Our primary outcomes of interest were first CVD event (fatal or non-fatal) after cohort entry, CVD mortality and all-cause mortality. CVD events were identified from linked hospital inpatient data using *International Classification of Diseases, Tenth Modification (ICD-10)* codes (in any diagnostic position) of I00–I99 (excluding I10–I15) and Q20 to Q28 (<https://www.ucl.ac.uk/health-informatics/caliber>).¹⁹ Deaths were identified from linked death registration data if the relevant codes appeared anywhere in the record. Events were identified from baseline to March 31, 2015 (administrative end of complete linkage follow-up).

Covariates

Ethnicity was self-reported at the nurse-validated baseline assessment. Self-report of diabetes mellitus status at baseline

was adjudicated using the UKB algorithm.²⁰ Deprivation was defined using the Townsend score, categorized into quintiles.²¹ Data on tobacco and alcohol consumption, and physical activity were obtained via the baseline touchscreen questionnaire. Smoking status was categorized into 6 groups: never smoker, ex-smoker, 1 to 9, 10 to 19, 20 to 29, and ≥ 30 cigarettes per day. Frequency of alcohol intake at baseline was grouped into the following categories: never, special occasions only, once or twice a month, once or twice a week, and (almost) daily. Number of days a week where participants undertook >10 minutes of moderate physical activity and vigorous physical activity were treated as separate categorical variables. We chose not to include additional data on number of minutes per session to create composite variable for metabolic hours per week as this greatly reduced the sample size. History of CVD at baseline was ascertained using both baseline interview and linked secondary care data. Use of lipid lowering and anti-hypertensive medications was reported and checked by a nurse, and blood pressure was measured. Data on high-density lipoprotein, low-density lipoprotein, and total cholesterol were not available.

Statistical Analysis

Separate, cause-specific Cox proportional hazard models (whereby deaths from other causes were censored), were fitted to estimate the association with each time to event outcome. Participants were considered at risk from 12 months after their baseline interview date to exclude events that could not be plausibly affected by baseline measures of body composition. In other words, we wanted to ensure that the results were not affected by reverse causality. This meant that participants experiencing the event of interest in the first 12 months were not included in the analysis. Follow-up time either: (1) ended at the first occurrence of the outcome; or (2) was censored at the end of the follow-up period or death (where death was not the outcome).

Risk of CVD events, CVD mortality, and all-cause mortality was compared across the 4 categories of body composition, stratified by history of CVD at baseline, with “optimal body composition” as the reference category. All models were adjusted for the following known risk factors for CVD/mortality which are also likely to impact body composition/strength: age (linear term), sex, smoking status, ethnic group, deprivation, diabetes mellitus status, alcohol consumption, and moderate physical activity at baseline. Vigorous physical activity was omitted from the models, as it was not found to improve model fit or change any estimates of interest once moderate physical activity was included. We did not adjust for use of lipid lowering medications at baseline, as use of statins has been shown to not be a good proxy for current cholesterol and is more indicative of health seeking behavior and vascular

risk;²² for which we could better adjust for using variables for smoking, alcohol, and physical activity. While blood pressure and cholesterol are strong predictors of CVD incidence, it is likely that these 2 variables are at least partly on the causal pathway between body composition and the outcomes or share common risk factors with our main exposures, making adjustment for them as “confounders” inappropriate and potentially misleading.²³

Tests for interactions between BMI and HGS were performed using Wald tests.

Participants with missing data for any model variable ($<11\%$) were excluded (Figure 1). Missing values for covariates such as smoking, alcohol, and physical activity were likely missing not at random, so multiple imputation was not appropriate. We used a complete case analysis under the assumption that, conditional on model covariates, missingness was independent of the outcome.²⁴

Sensitivity Analysis

To further assess possible reverse causality, all analyses using the 4-level variable for body composition were re-run excluding the first 2, 3, then 4 years of follow-up. Secondly, since it is possible that the inclusion of less severe CVD events in the composite CVD outcome may reduce any association or interaction, we also looked at coronary heart disease (CHD) (ICD-10 codes I20–25, I46, I47 and I49) as an additional outcome.

Secondary Analyses

To investigate whether other measures of muscle quality or adiposity may provide differing results we repeated the primary analysis using skeletal muscle mass index (SMMI) in place of hand-grip strength and replacing BMI with waist-hip-ratio (WHR) and then with fat mass (%). SMMI was calculated from the bioelectrical impedance measures using the Janssen et al equation, then taking the bottom 40% of the distribution as the definition of sarcopenia.^{25–27} The cut-off for obesity for WHR was defined as ≥ 0.95 for men and ≥ 0.80 for women. Fat mass percentage does not have a well-defined cut-off in terms of obesity, therefore we used this metric to compare differences between quintiles only.

Mendelian Randomization

After excluding potentially related samples, variants for BMI, WHR, and HGS, were screened on Hardy-Weinberg equilibrium (threshold $-\log_{10}(P \text{ value}) \leq 1 \times 10^{-6}$), and (where relevant) imputation quality (Table S1). We used previously identified independent variants to calculate weighted genetic instruments for BMI, WHR, and HGS.^{28–31} Some of the identified




Figure 1. Flowchart of numbers included in study for observational analyses and Mendelian randomization. BMI indicates body mass index; HGS, hand-grip strength; QC, quality control; WHR, waist-hip-ratio.

variants did not pass quality control in our data and were therefore excluded from the genetic score (Tables S2 through S4). Weights were derived based on variant to phenotype associations. Two sets of weights were calculated, using internal and then external data^{28–30} to prevent weak instrument bias. Genetic score (GS) instrument strength was quantified using the F-statistic of a linear regression model relating the GS to the intermediate phenotypes, with a statistic of ≥ 10 indicating the instrument had sufficient strength. Variants for HGS were taken from a previous study²⁹ using the UKB as there are no published independent genome-wide association studies. These weighted GS were subsequently associated with outcomes using Cox proportional hazard models, allowing for an interaction between BMI and HGS using a factorial MR (FMR) design.³² The FMR explored interactions by first categorizing the GS into high versus low (cut at the median), and combining these in a 4-level categorical variable, and then by entering the 2 scores as continuous linear terms with an interaction. In line with the observational analysis, we then repeated this using WHR instead of BMI as a secondary analysis, and also considered CHD events and mortality in a sensitivity analysis. Interaction *P* values were obtained from likelihood ratio tests. To investigate pleiotropy, we also examined associations between individual variants used to develop the GS for each phenotype and other measured risk factors for CVD and mortality.

Multiple Testing

Throughout our analyses, we made no adjustment for multiple testing. Provided results are appropriately interpreted, the adjustment is unnecessary, particularly when the multiple

outcomes/exposures being tested are correlated as is the case here.³³ We aimed to focus on the overall pattern of results, and used the CIs to provide the range of effect estimates for which our data were compatible rather than looking at whether a particular interval included or excluded the null. By the same argument, for the statistical tests of interaction, we also considered overall pattern of results rather than focusing on individual *P* values.

Results

A total of 452 931 participants had complete data on BMI, HGS, and all covariates (Figure 1). Baseline characteristics stratified by body composition (according to BMI and HGS) are shown in Table 1. Twenty percent of participants had obesity but not sarcopenia, 11% had sarcopenia but not obesity, and 4% had both (sarcopenic obesity). Mean follow-up time after excluding the first 12 months was 5.1 years. During follow-up, there were 30 842 fatal and non-fatal CVD events, and 11 336 deaths (3273 CVD).

Observational Analysis

In participants with no history of CVD, BMI-defined obesity in the absence of sarcopenia was associated with an increased risk of CVD events (adjusted hazard ratio [HR], 1.29 [1.24–1.35]). The analogous estimate for those with prior CVD was 1.23 (1.16–1.30) (Figure 2). Obesity in the absence of sarcopenia was also associated with an increased risk of mortality (Figure 2).

Sarcopenia without obesity had a more modest association with risk of CVD events, relative to optimal body composition, regardless of prior CVD (HR range, 1.04–1.09). Estimated

Table 1. Baseline Characteristics of 452 931 Individuals in the UKB With BMI and Hand-Grip Strength Measures and Complete Covariate Data, Stratified By Body Composition as Defined By BMI and Hand-Grip Strength

Denominator	Optimal		Obese		Sarcopenic		Sarcopenic Obese	
	296 567 (65%)		89 906 (20%)		48 250 (11%)		18 208 (4%)	
Follow-up time (y) (median, IQR)	6.18	5.48–6.86	6.17	5.46–6.88	6.00	5.31–6.67	6.01	5.32–6.72
Death during follow-up, n (%)	6710	2.3%	2790	3.1%	1822	3.8%	827	4.5%
CVD death during follow up n (%)	1701	0.6%	991	1.1%	557	1.2%	308	1.7%
Any CVD event during follow-up, n (%)	17 082	5.8%	8135	9.1%	3759	7.8%	2314	12.7%
Mean age at baseline (SD)	55.9	8.2	56.2	7.9	59.5	7.3	59.4	7.1
Male, n (%)	140 302	47.3%	45 979	51.1%	13 820	28.6%	5467	30.0%
Ethnic group, n (%)								
White	284 023	95.8%	85 297	94.9%	44 518	92.3%	16 826	92.4%
South Asian	3369	1.1%	869	1.0%	1657	3.4%	527	2.9%
African Caribbean	3495	1.2%	2237	2.5%	528	1.1%	420	2.3%
Other	5680	1.9%	1503	1.7%	1547	3.2%	435	2.4%
Townsend deprivation score (mean, SD)	−1.6	2.9	−1.0	3.2	−1.2	3.1	−0.4	3.4
Comorbidities, n (%)								
Type 1 diabetes mellitus	827	0.3%	335	0.4%	229	0.5%	111	0.6%
Type 2 diabetes mellitus	7149	2.4%	8786	9.8%	2241	4.6%	2813	15.4%
History of CHD	11 599	3.9%	7061	7.9%	3077	6.4%	2146	11.8%
History of CVD (CHD, stroke, angina)	33 226	11.2%	15 140	16.8%	7585	15.7%	4321	23.7%
Smoking status, n (%)								
Never smoker	208 804	70.4%	57 030	63.4%	34 242	71.0%	11 914	65.4%
Ex-smoker	65 794	22.2%	27 014	30.0%	10 341	21.4%	5144	28.3%
Current-smoker	21 969	7.4%	5862	6.5%	3667	7.6%	1150	6.3%
1 to 9 cigarettes per day	4760	1.6%	920	1.0%	790	1.6%	171	0.9%
10 to 19 cigarettes per day	9407	3.2%	2347	2.6%	1681	3.5%	473	2.6%
20 to 29 cigarettes per day	6274	2.1%	1920	2.1%	952	2.0%	378	2.1%
30+ cigarettes per day	1528	0.5%	675	0.8%	244	0.5%	128	0.7%
Alcohol consumption, n (%)								
Never	18 696	6.3%	7650	8.5%	5638	11.7%	2895	15.9%
Special occasions only	27 608	9.3%	12 837	14.3%	6814	14.1%	3828	21.0%
Once or twice a month	30 881	10.4%	12 209	13.6%	5255	10.9%	2438	13.4%
Once or twice a week	76 936	25.9%	24 131	26.8%	12 034	24.9%	4312	23.7%
3 or 4 times a week	75 610	25.5%	18 285	20.3%	9637	20.0%	2637	14.5%
Almost daily	66 836	22.5%	14 794	16.5%	8872	18.4%	2098	11.5%
PA (median [IQR])								
Days of moderate PA per week	4	[2,6]	3	[1,5]	4	[2,6]	3	[1,5]
Days of vigorous PA per week	2	[0,3]	1	[0,3]	1	[0,3]	0	[0,2]
Anthropometric/metabolic measures (mean, SD)								
Systolic blood pressure	136.47	18.62	142.01	17.69	136.50	19.27	141.33	18.64
BMI, kg/m ²	25.32	2.69	33.81	3.74	25.19	2.82	34.37	4.74
Whole body fat mass (%)	28.80	7.51	37.62	7.75	31.83	7.31	41.18	6.98
Waist-hip-ratio	0.85	0.08	0.92	0.09	0.85	0.08	0.91	0.09

Continued

Table 1. Continued

Denominator	Optimal		Obese		Sarcopenic		Sarcopenic Obese	
	296 567 (65%)		89 906 (20%)		48 250 (11%)		18 208 (4%)	
Skeletal muscle mass index, kg/m ²	7.63	1.39	8.65	1.50	6.96	1.30	7.98	1.49
Grip strength, kg	34.14	10.02	34.97	10.54	17.74	5.63	17.35	11.29

BMI indicates body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; IQR, interquartile range; PA, physical activity.

associations with mortality were larger (HR range, 1.39–1.72) (Figure 2).

Sarcopenic obesity (defined by HGS and BMI) was associated with the highest risk of CVD events compared with the other 3 categories of body composition, with no clear differences between those with and without prior CVD. For mortality outcomes, sarcopenic obesity individuals had estimated risks consistent with sarcopenic non-obese individuals, again with minimal differences by CVD history (Figure 2).

There was no clear evidence of an interaction between sarcopenia and obesity for CVD events. The relative effects of obesity appeared similar with and without the presence of sarcopenia, and vice versa, with and without prior CVD (Figure 2). Statistically, there was evidence of interactions between sarcopenia and obesity for mortality outcomes, but the direction of this was suggestive of a reduced relative effect of obesity in those who were sarcopenic. Further, the estimated size of the interactions was not large in magnitude (Figure 2).




Figure 2. Estimated association between body composition and fatal/non-cardiovascular disease (CVD) events and cause-specific and all-cause mortality. Obesity measured as body mass index >30, sarcopenia measured as HGS <30 kg men and <20 kg women.

Table 2. Adjusted* Hazard Ratios (with 95% CI) of All-Cause and CVD Mortality, and Combined Fatal/Non-CVD Events By Quintiles of BMI and HGS, in Patients With No Prior History of CVD

	HGS Quintile (kg)					
	43 to 90	35 to 42	29 to 34	23 to 28	0 to 22	P Value for Interaction
BMI quintile (kg/m ²)						
All-cause mortality						
12 to 23	1 (ref)	1.37 (1.12–1.69)	1.52 (1.23–1.87)	1.84 (1.50–2.26)	2.23 (1.82–2.73)	0.169
23 to 26	0.92 (0.75–1.15)	1.17 (0.96–1.44)	1.63 (1.33–2.00)	1.70 (1.38–2.09)	1.88 (1.53–2.31)	
26 to 28	1.02 (0.83–1.24)	1.17 (0.96–1.42)	1.40 (1.14–1.72)	1.62 (1.31–2.00)	1.92 (1.56–2.37)	
28 to 31	1.14 (0.94–1.39)	1.23 (1.01–1.49)	1.51 (1.23–1.85)	1.67 (1.35–2.06)	2.05 (1.67–2.52)	
31 to 60	1.35 (1.10–1.65)	1.39 (1.14–1.70)	1.67 (1.36–2.05)	1.83 (1.49–2.26)	2.07 (1.69–2.53)	
Fatal/non-fatal CVD						
12 to 23	1 (ref)	0.92 (0.77–1.09)	1.06 (0.90–1.25)	1.03 (0.87–1.22)	0.96 (0.81–1.14)	0.376
23 to 26	0.98 (0.83–1.15)	1.03 (0.88–1.21)	1.06 (0.90–1.25)	1.06 (0.90–1.26)	1.08 (0.92–1.28)	
26 to 28	1.11 (0.95–1.29)	1.13 (0.96–1.31)	1.10 (0.93–1.30)	1.14 (0.96–1.35)	1.11 (0.94–1.32)	
28 to 31	1.15 (0.98–1.34)	1.19 (1.02–1.39)	1.22 (1.04–1.44)	1.18 (0.99–1.40)	1.34 (1.13–1.58)	
31 to 60	1.51 (1.30–1.76)	1.31 (1.12–1.54)	1.60 (1.37–1.87)	1.48 (1.25–1.74)	1.49 (1.27–1.75)	
Fatal CVD						
12 to 23	1 (ref)	1.38 (0.90–2.12)	1.39 (0.88–2.18)	1.80 (1.14–2.83)	2.63 (1.71–4.06)	0.225
23 to 26	0.94 (0.60–1.47)	1.20 (0.79–1.83)	1.52 (0.98–2.35)	2.32 (1.50–3.59)	2.38 (1.53–3.70)	
26 to 28	1.07 (0.71–1.64)	1.15 (0.76–1.74)	1.32 (0.85–2.05)	1.54 (0.96–2.46)	2.12 (1.35–3.34)	
28 to 31	1.30 (0.87–1.96)	1.35 (0.90–2.03)	1.72 (1.13–2.63)	1.91 (1.22–3.00)	3.06 (2.00–4.70)	
31 to 60	1.63 (1.08–2.45)	1.69 (1.13–2.54)	2.54 (1.69–3.82)	2.89 (1.89–4.42)	2.55 (1.66–3.92)	

BMI indicates body mass index; CVD, cardiovascular disease; HGS, hand-grip strength.

*Adjusted for age, sex, ethnicity, and baseline measures of smoking, alcohol consumption, diabetes mellitus status, physical activity and deprivation.

Risk of CVD events increased linearly by quintile of BMI, but within BMI quintile, there was no clear pattern of an association with HGS (Tables 2 and 3). In contrast, for the mortality outcomes, there was less evidence of an association with BMI quintile, but there was clear pattern of decreasing risk with increasing HGS quintile. A “U” shaped association was observed for the effect of BMI on CVD mortality and all-cause mortality in the lowest quintile of HGS, particularly for those with a prior history of CVD. In general, however, there was little evidence of non-linearity (Tables 2 and 3). There was no other strong suggestion that the effect of BMI differed by HGS, or vice versa, as reflected in both the estimates of effect and interaction *P* values.

Sensitivity Analyses

Extending the exclusion period at the beginning of follow-up appeared to make minimal differences to the results (Figure S1). Results for CHD events and mortality had similar pattern to those for CVD events and mortality as a whole, though in general effect sizes for the effect of

obesity were larger in magnitude (Figure S2 and Tables S5 and S6).

Secondary Analyses

The proportion of individuals with sarcopenic obesity at baseline differed substantially for each of the 4 definitions; varying from 2% using BMI and SMMI, to 17% using WHR and SSMI (Table S7). Associations between sarcopenia as defined by SMMI and all outcomes were generally null compared with those with normal body composition (Figure S3). Further, there was no consistent evidence of an association between SMMI quintiles and any outcome, regardless of BMI quintile (Tables S8 and S9).

Using WHR instead of BMI gave similar results for all analyses performed (Figure S4 and Tables S10 and S11). Using fat mass quintiles gave a similar pattern of results as BMI, though there was stronger evidence for an interaction with HGS. However, this appeared to be driven by the same U-shaped association observed for BMI at the lower HGS quintiles. (Tables S12 and S13).

Table 3. Adjusted* Hazard Ratios (with 95% CI) of All-Cause and CVD Mortality, and Combined Fatal/Non-CVD Events By Quintiles of BMI and HGS, in Patients With Prior History of CVD

	HGS Quintile (kg)					P Value for Interaction
	43 to 90	35 to 42	29 to 34	23 to 28	0 to 22	
BMI quintile (kg/m ²)						
All-cause mortality						
12 to 23	1 (ref)	1.49 (0.95–2.32)	2.03 (1.31–3.13)	2.95 (1.92–4.53)	3.45 (2.27–5.24)	0.007
23 to 26	1.31 (0.84–2.04)	1.33 (0.87–2.03)	1.86 (1.22–2.85)	2.10 (1.35–3.25)	2.15 (1.39–3.32)	
26 to 28	1.23 (0.81–1.89)	1.30 (0.86–1.96)	1.93 (1.28–2.92)	1.88 (1.21–2.91)	2.01 (1.31–3.09)	
28 to 31	1.21 (0.80–1.83)	1.44 (0.96–2.16)	1.50 (0.99–2.26)	1.63 (1.05–2.51)	2.01 (1.32–3.07)	
31 to 60	1.45 (0.96–2.18)	1.54 (1.03–2.29)	1.58 (1.05–2.37)	2.31 (1.53–3.48)	2.74 (1.82–4.10)	
Fatal/non-fatal CVD						
12 to 23	1 (ref)	1.06 (0.80–1.39)	1.26 (0.96–1.65)	1.14 (0.86–1.5)	1.25 (0.96–1.63)	0.070
23 to 26	1.11 (0.85–1.45)	1.33 (1.03–1.70)	1.29 (1.00–1.68)	1.19 (0.90–1.56)	1.26 (0.97–1.64)	
26 to 28	1.29 (1.00–1.65)	1.31 (1.03–1.68)	1.29 (1.00–1.67)	1.36 (1.05–1.78)	1.30 (1.00–1.69)	
28 to 31	1.24 (0.97–1.58)	1.32 (1.04–1.69)	1.21 (0.94–1.56)	1.3 (1.00–1.69)	1.47 (1.14–1.89)	
31 to 60	1.66 (1.30–2.11)	1.42 (1.12–1.80)	1.68 (1.32–2.14)	1.59 (1.24–2.04)	1.79 (1.41–2.29)	
Fatal CVD						
12 to 23	1 (ref)	2.34 (1.02–5.33)	3.40 (1.51–7.65)	4.69 (2.07–10.61)	6.76 (3.06–14.93)	0.146
23 to 26	1.82 (0.79–4.18)	2.45 (1.11–5.39)	2.64 (1.18–5.93)	3.87 (1.71–8.74)	4.12 (1.82–9.29)	
26 to 28	2.03 (0.91–4.51)	2.37 (1.09–5.15)	3.53 (1.62–7.69)	3.57 (1.59–8.02)	3.09 (1.36–7.02)	
28 to 31	1.57 (0.71–3.49)	2.65 (1.23–5.71)	2.66 (1.22–5.81)	3.35 (1.51–7.45)	3.97 (1.79–8.77)	
31 to 60	2.85 (1.32–6.16)	2.96 (1.38–6.34)	3.31 (1.54–7.13)	4.26 (1.96–9.26)	5.21 (2.41–11.28)	

BMI indicates body mass index; CVD; cardiovascular disease; HGS, hand-grip strength.

*Adjusted for age, sex, ethnicity, and baseline measures of smoking, alcohol consumption, diabetes mellitus status, physical activity and deprivation.

MR Analysis

A total of 111 348 participants contributed to MR (Figure 1). The median genetically predicted values for BMI, WHR, and HGS were 27.5 kg/m², 0.88, and 32.2 kg, respectively (Figure 3). The F statistics for the 3 scores were 2009, 500, and 128 using external weights; and 2250, 569, and 137 with internal weights for BMI, WHR, and HGS, respectively, indicating that both internal and external genetic scores (GS) were strong instruments.

The factorial analysis suggested no statistical evidence of interaction between BMI and HGS (Figure 4). In general, there was no clear evidence of an increased risk of fatal/non-fatal CVD for any combination of genetic scores for BMI and HGS. All HRs were close to 1 for both internal and externally weighted GS (maximum HR: 1.04, minimum HR: 0.99). Broadly, low HGS was estimated to increase the risk of mortality outcomes compared with high HGS, irrespective of obesity category (Figure 4), though the effect sizes were smaller than those from the observational analysis. In participants with high HGS scores, there was no evidence of any effect of BMI on CVD and

all-cause mortality (HRs 1.09 [0.91–1.30] and 0.96 [0.87–1.06], respectively for externally weighted GS, and 0.99 [0.83–1.18] and 0.98 [0.89–1.08] for internally weighted GS. This lack of BMI effect was also observed in those with low HGS (Figure 4).

Using internally weighted GS as continuous variables instead of dichotomizing at the median, there remained no evidence for an interaction between BMI and HGS for any of the outcomes (Table 4). As with the dichotomized risk scores, the estimated HRs per unit increase in BMI for all outcomes from these models were estimated to small in magnitude (HR range, 1.00–1.04) and all CIs included 1. This was also true for the effect of grip strength on fatal/non-fatal CVD (HR 1.02 [0.97–1.08]). However, each unit increase in HGS was estimated to reduce the relative risk of all-cause and CVD mortality by around 10% at the median BMI score (HR 0.86 [0.79–0.94] and 0.88 [0.75–1.02], respectively).

Results using genetic scores for WHR instead of BMI were similar (Figure S5 and Table S14), as were results for CHD and CHD mortality (Figure S6 and Table S14).




Figure 3. Distributions of genetic risk scores for hand-grip strength (HGS) (kg) (top), BMI (kg/m²) (middle) and waist-hip-ratio (WHR) (bottom). BMI indicates body mass index; HGS, hand-grip strength; WHR, waist-hip-ratio.

Assessment of Potential Pleiotropy

Three BMI variants were identified that were genome-wide significantly associated with systolic blood pressure (SBP), WHR, and use of lipid-lowering drugs (Figure 5A). One WHR SNP was found to also be associated with HGS. Although not reaching genome-wide statistical significance, many SNPs had relatively large beta estimates for an association with SBP (Figure 5B).

Discussion

In a study of 450 000 UK adults, we found no evidence for a healthy obesity phenotype in association with muscle strength using observed phenotypes in a multivariable regression or using Mendelian randomization approaches in 111 348 individuals with available genetic and phenotype data. Increased BMI was linearly associated with increased risk of both CVD events and mortality (CVD and all-cause) to a similar degree. Greater muscle quality, as measured by HGS or by variants acting as instrumental variables were estimated to reduced CVD and all-cause mortality risk but showed less association (both statistically and in magnitude) with fatal/non-fatal CVD events. Our overall findings do not support a “U” or “J” shaped association between adiposity and any outcome; however, few participants were clinically underweight. There was no consistent evidence that the effect of adiposity was modified by grip strength or skeletal muscle mass, and vice-versa, suggesting that the negative effects of obesity are not reduced in those with greater strength, or that the observed reduction in risk of mortality with increasing strength is not negated by excess adiposity.

Previous studies that have examined the joint effect of grip strength and obesity are limited by small sample size and potential for reverse causality.^{34,35} For the latter issue, our findings were unchanged when we excluded events occurring in the first and subsequent 2, 3, and 4 years of follow-up, and when stratified by prior history of CVD. UKB participants are relatively young; relatively small numbers have pre-existing disease or extreme anthropometric phenotypes,³⁶ which could explain this. Indeed, the proportion of clinically underweight, at <1%, and obese, at 4%, was low, also making it harder to detect non-linear associations if they exist.

From secondary analyses, our finding of similarity between BMI and WHR in terms of subsequent risk is in line with a recent comparative study of 4 UK-based cohorts.¹¹ The finding that muscle strength defined by HGS appears to be of greater prognostic value than muscle mass defined by SMMI adds to a growing body of evidence;^{5,37}

In contrast to a recent study also using the UKB,⁴ we found no clear evidence of an effect of sarcopenia on incident or recurring CVD events. However, the existing study used a narrower definition of CVD which may explain the stronger effects observed.

In our observational analysis, we found that sarcopenia was strongly related to mortality, consistent with existing observational evidence.^{3,4} Despite similar findings in those with and without prior CVD suggesting that reverse causality had little impact on findings, we cannot exclude the possibility of some misclassification of prior CVD because of undiagnosed disease at baseline. However, the number of undiagnosed individuals would have to be large to explain this fully.




Figure 4. Relative hazard of fatal/non-fatal cardiovascular disease (CVD) events and cause specific and all-cause mortality according to category of body composition as defined by genetic scores estimated from both external in internal weights in a factorial Mendelian randomization analysis.

Further, in contrast to a previous, smaller MR study,²⁹ the harmful effect of lower genetically predicted HGS on mortality outcomes was replicated when using genetically predicted HGS, most notably for all-cause mortality. This suggests it is even less likely that the adverse effect of sarcopenia on mortality is solely attributable to reverse causality.

Potential causal mechanisms for the observed association between HGS and mortality outcomes include the effect of

skeletal muscle on exercise capacity, itself a strong predictor of mortality, via maintenance of preload and cardiac output during physical activity.³⁸

The MR analysis also found no evidence of an interaction between adiposity and HGS. In our observational analysis, there was some suggestion of a protective effect of obesity in sarcopenic individuals for mortality outcomes, which resulted in some statistical evidence of interactions. This direction of

Table 4. Results of MR Using Continuous Genetic Scores* With Interaction Between HGS and BMI

Outcome	HR Per Unit Increase in HGS At the Median BMI	HR Per Unit Increase in BMI at the Median HGS	Interaction Term (HR)	Interaction P Value
Fatal/non-fatal CVD	1.02 (0.97–1.08)	1.04 (1.00–1.07)	0.97 (0.89–1.05)	0.434
CVD mortality	0.88 (0.75–1.02)	1.03 (0.94–1.13)	1.12 (0.89–1.40)	0.344
All-cause mortality	0.86 (0.79–0.94)	1.00 (0.96–1.06)	1.08 (0.95–1.22)	0.239

BMI indicates body mass index; CVD, cardiovascular disease; HGS, hand-grip strength; HR, hazard ratio; WHR, waist-hip-ratio.

*Genetic risk score derived from internal weights.




Figure 5. Associations between HGS (left) BMI (middle) and WHR (right) variants, and possible pleiotropic variables. BMI indicates body mass index; COPD, chronic obstructive pulmonary disease; HGS, hand-grip strength; WHR, waist-hip-ratio; SBP, systolic blood pressure.

interaction is not consistent with the healthy obese hypothesis and may be a consequence of un-measured confounding by frailty.

A key strength of the study was the additional use of MR analyses, an important tool in establishing causality. However, the following issues deserve consideration. Given the sparsity of GWAS data on HGS, SNP selection²⁹ as well as estimation utilized the same UKB sample, resulting in a degree of selection bias (eg, inflated weights). This type of selection bias decreases to zero as sample size increases.³⁹ Given the size of the UKB we expect this source of bias to have minimal influence on presented results. Our results are also strengthened by the finding that using external weights for BMI, WHR, and HGS showed similar results, and the F statistics for both internal and external weights were large for all predicted phenotypes.

An alternative explanation for our findings is that genes that predict grip strength may also predict other phenotypes associated with health status (pleiotropic effects). Because of the focus on factorial MR, we were unable to use more robust methods such as MR-egger that protect against bias because of horizontal pleiotropy and acknowledge this may be a limitation of our study. However, we were able to explore the pleiotropy potential of the used variants by examining the associations between the genetic risk scores and other CVD risk factors. Here, we found only 3 genome-wide significant associations with potentially pleiotropic pathways such as SBP and use of lipid-lowering drugs. However, these pathways may well lie on the causal pathway between our exposures (BMI, WHR, and HGS) and CVD, which does not bias or invalidate our results (horizontal pleiotropy). Having said this,

there may exist alternative pleiotropic pathways that we were unable to examine given the available data.

As expected, distributions of the genetic risk scores for BMI, WHR, and HGS showed far less variation than the observed phenotypes. Genetically predicted HGS ranged from 30 to 35 kg, BMI ranged from 27 to 31. This may explain the lack of effect of observed genetic associations and small HR estimates for BMI and WHR on any of the outcomes when dichotomized at the median genetic score. This could also contribute to the lack of interaction observed here. Further, we cannot exclude the possibility that we were underpowered to detect the interactions in this analysis given the smaller effect sizes, though given our sample size we believe this unlikely.

Our study is limited by mean follow-up period of 5 years, limiting the number of incident events available for analysis. Indeed, the number of deaths occurring in our sample (11 336) was comparable with the number of deaths observed in the 2016 meta-analysis (14 306), which had a far smaller overall sample size. However, the previously mentioned healthy participant bias may explain the overall lower event rates and limited our ability to look at people with severe obesity but should not bias associations between obesity and outcomes.

A further limitation is that the lack of repeated measures of obesity and sarcopenia prevent us from examining the role of prolonged exposure or changes in exposure, which may be important predictors of our outcomes of interest. Other risk factors for our outcomes may also have been time varying, making choice of covariates for confounder adjustment complex. Since the data available for both exposure and

covariates were all measured at a single time point, our analysis relies on making assumptions about which covariates are likely to have influenced the exposure at that point, versus which may have been a consequence of the measured exposure (so should not be adjusted for). Provided the assumptions of MR were satisfied, our analysis using genetic risk scores is robust to both of these limitations of the observational analysis.

Conclusions

Our analyses do not support the concept of a “healthy obese” phenotype in relationship to muscle mass or grip strength. WHR, BMI, and fat mass defined obesity appear similar in their association with future cardiovascular risk and mortality, in that in general, increased adiposity increases risk. Lower-grip strength was associated with increased risks of cardiovascular and all-cause mortality in a multivariable regression and MR analysis, suggesting reverse causality may not be the sole explanation. Grip strength appears to be a good prognostic indicator for mortality risk in adults with and without obesity, though it is not yet clear whether interventions to improve muscle strength would directly decrease risk.

Acknowledgments

This research has been conducted using the UK Biobank Resource under application number 21893.

Sources of Funding

This work was funded by a Diabetes UK/British Heart Foundation award to Prof. Chaturvedi and Prof. Smeeth, award number [15/0005250]. Dr. Mathur is supported by a Sir Henry Wellcome Postdoctoral Fellowship from the Wellcome Trust (WT/201375/Z/16/Z). Prof. Bhaskaran holds a Sir Henry Dale fellowship jointly funded by the Wellcome Trust and the Royal Society (107731/Z/15/Z).

Disclosures

None.

References

- Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? *Ann Intern Med*. 2013;159:758.
- Chin SO, Rhee SY, Chon S, Hwang Y-C, Jeong I-K, Oh S, Ahn KJ, Chung HY, Woo J, Kim S-W, Kim J-W, Kim YS, Ahn H-Y. Sarcopenia is independently associated with cardiovascular disease in older Korean adults: the Korea National Health and Nutrition Examination Survey (KNHANES) from 2009. *PLoS One*. 2013;8:e60119.
- Strand BH, Cooper R, Bergland A, Jørgensen L, Schirmer H, Skirbekk V, Emaus N. The association of grip strength from midlife onwards with all-cause and cause-specific mortality over 17 years of follow-up in the Tromsø Study. *J Epidemiol Community Health*. 2016;70:1214–1221.
- Celis-Morales CA, Welsh P, Lyall DM, Steell L, Petermann F, Anderson J, Iliodromiti S, Sillars A, Graham N, Mackay DF, Pell JP, Gill JMR, Sattar N, Gray SR. Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: prospective cohort study of half a million UK Biobank participants. *BMJ*. 2018;361:k1651.
- Tian S, Xu Y. Association of sarcopenic obesity with the risk of all-cause mortality: a meta-analysis of prospective cohort studies. *Geriatr Gerontol Int*. 2016;16:155–166.
- Barbat-Artigas S, Rolland Y, Vellas B, Aubertin-Leheudre M. Muscle quantity is not synonymous with muscle quality. *J Am Med Dir Assoc*. 2013;14:852.e1–852.e7.
- Cheng TO. Central obesity is a more sensitive predictor of cardiovascular disease than body mass index in the Chinese population. *Int J Cardiol*. 2009;135:385.
- Shields M, Tremblay MS, Gorber SC, Janssen I. Abdominal obesity and cardiovascular disease risk factors within body mass index categories. *Health Rep*. 2012;23:826–834.
- Park YS, Kim J-S. Obesity phenotype and coronary heart disease risk as estimated by the Framingham risk score. *J Korean Med Sci*. 2012;27:243.
- Goh LGH, Dhaliwal SS, Welborn TA, Lee AH, Della PR. Anthropometric measurements of general and central obesity and the prediction of cardiovascular disease risk in women: a cross-sectional study. *BMJ Open*. 2014;4:e004138.
- Taylor AE, Ebrahim S, Ben-Shlomo Y, Martin RM, Whincup PH, Yarnell JW, Wannamethee SG, Lawlor DA. Comparison of the associations of body mass index and measures of central adiposity and fat mass with coronary heart disease, diabetes, and all-cause mortality: a study using data from 4 UK cohorts. *Am J Clin Nutr*. 2010;91:547–556.
- Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet*. 2014;23:R89–R98.
- UK Biobank. UK Biobank: Protocol for a large-scale prospective epidemiological resource UK Biobank Coordinating Centre Stockport. 2007. Available at: <https://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf>.
- Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, Collins R. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*. 2015;12:1–10.
- UK Biobank. UKB: Resource 100232: Grip-strength measurement using ACE. Available at: <https://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=100232>.
- Hamilton GF, McDonald C, Chenier TC. Measurement of grip strength: validity and reliability of the sphygmomanometer and Jamar grip dynamometer. *J Orthop Sport Phys Ther*. 1992;16:215–219.
- Bellace J V, Healy D, Besser MP, Byron T, Hohman L. Validity of the Dexter Evaluation System's Jamar dynamometer attachment for assessment of hand grip strength in a normal population. *J Hand Ther*. 2000;13:46–51.
- Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel J-P, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. *Age Ageing*. 2010;39:412–423.
- Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. *Circulation*. 2013;127:e6–e245.
- Eastwood SV, Mathur R, Atkinson M, Brophy S, Sudlow C, Flaig R, De Lusignan S, Allen N, Chaturvedi N. Algorithms for the capture and adjudication of prevalent and incident diabetes in UK Biobank. *PLoS One*. 2016;11.
- Townsend P. Deprivation. *J Soc Policy*. 1987;16:125–146.
- Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, Solomon DH. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. *Am J Epidemiol*. 2007;166:348–354.
- Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. *Epidemiology*. 2009;20:488–495.
- White IR, Carlin JB. Bias and efficiency of multiple imputation compared with complete-case analysis for missing covariate values. *Stat Med*. 2010;29:2920–2931.

25. Baumgartner RN. Body composition in healthy aging. *Ann N Y Acad Sci*. 2000;904:437–448.
26. Atkins JL, Whincup PH, Morris RW, Lennon LT, Papacosta O, Wannamethee SG. Sarcopenic obesity and risk of cardiovascular disease and mortality: a population-based cohort study of older men. *J Am Geriatr Soc*. 2014;62:253–260.
27. Janssen I, Heymsfield SB, Baumgartner RN, Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. *J Appl Physiol*. 2000;89:465–471.
28. Locke A, Kahali B, Berndt S, Justice A, Pers T. Genetic studies of body mass index yield new insights for obesity biology. *Nature*. 2015;518:197–206.
29. Willems SM, Wright DJ, Day FR, Trajanoska K, Joshi PK, Morris JA, Matteini AM, Garton FC, Grarup N, Oskolkov N, Thalamuthu A, Mangino M, Liu J, Demirkan A, Lek M, Xu L, Wang G, Oldmeadow C, Gaulton KJ, Lotta LA, Miyamoto-Mikami E, Rivas MA, White T, Loh PR, Aadahl M, Amin N, Attia JR, Austin K, Benyamin B, Brage S, Cheng YC, Cichosz P, Derave W, Eriksson KF, Eynon N, Linneberg A, Lucia A, Massidda M, Mitchell BD, Miyachi M, Murakami H, Padmanabhan S, Pandey A, Papadimitriou I, Rajpal DK, Sale C, Schnurr TM, Sessa F, Shrine N, Tobin MD, Varley I, Wain LV, Wray NR, Lindgren CM, MacArthur DG, Waterworth DM, McCarthy MI, Pedersen O, Khaw KT, Kiel DP, Pitsiladis Y, Fuku N, Franks PW, North KN, Van Duijn CM, Mather KA, Hansen T, Hansson O, Spector T, Murabito JM, Richards JB, Rivadeneira F, Langenberg C, Perry JRB, Wareham NJ, Scott RA, Oei L, Zheng HF, Forgetta V, Leong A, Ahmad OS, Laurin C, Mokry LE, Ross S, Elks CE, Bowden J, Warrington NM, Murray A, Ruth KS, Tslilidis KK, Medina-Gómez C, Estrada K, Bis JC, Chasman DI, Demissie S, Enneman AW, Hsu YH, Ingvarsson T, Kähönen M, Kammerer C, Lacroix AZ, Li G, Liu CT, Liu Y, Lorentzon M, Mägi R, Mihailov E, Milani L, Moayyeri A, Nielson SW, Ridker PM, Siggeirsdottir K, Sigurdsson G, Stefansson K, Trompet S, Thorleifsson G, Vandenput L, Van Der Velde N, Viikari J, Xiao SM, Zhao JH, Evans DS, Cummings SR, Cauley J, Duncan EL, De Groot LCPGM, Esko T, Gudnason V, Harris TB, Jackson RD, Jukema JW, Ikram AMA, Karasik D, Kaptoge S, Kung AWC, Lehtimäki T, Lytikäinen LP, Lips P, Luben R, Metspalu A, Van Meurs BJ, Minster RL, Orwoll E, Oei E, Psaty BM, Raitakari OT, Ralston SW, Ridker PM, Robbins JA, Smith AV, Stykarsdottir U, Tranah GJ, Thorsteinsdottir U, Uitterlinden AG, Zmuda J, Zillikens MC, Ntani EE, Evangelou E, Ioannidis JPA, Evans DM, Ohlsson C. Large-scale GWAS identifies multiple loci for hand grip strength providing biological insights into muscular fitness. *Nat Commun*. 2017;8:16015.
30. Dale CE, Fatemifar G, Palmer TM, White J, Prieto-Merino D, Zabaneh D, Engmann JEL, Shah T, Wong A, Warren HR, McLachlan S, Trompet S, Moldovan M, Morris RW, Sofat R, Kumari M, Hyppönen E, Jeffers BJ, Gaunt TR, Ben-Shlomo Y, Zhou A, Gentry-Maharaj A, Ryan A, de Mutsert R, Noordam R, Caulfield MJ, Jukema JW, Worrall BB, Munroe PB, Menon U, Power C, Kuh D, Lawlor DA, Humphries SE, Mook-Kanamori DO, Sattar N, Kivimäki M, Price JF, Davey Smith G, Dudbridge F, Hingorani AD, Holmes MV, Casas JP, Casas JP. Causal associations of adiposity and body fat distribution with coronary heart disease, stroke subtypes, and type 2 diabetes mellitus: clinical perspective. *Circulation*. 2017;135:2373–2388.
31. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Mägi R, Strawbridge RJ, Pers TH, Fischer K, Justice AE, Workalemahu T, Wu JMW, Buchkovich ML, Heard-Costa NL, Roman TS, Drong AW, Song C, Gustafsson S, Day FR, Esko T, Fall T, Kutalik Z, Luan J, Randall JC, Scherag A, Vedantam S, Wood AR, Chen J, Fehrmann R, Karjalainen J, Kahali B, Liu C-T, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bragg-Gresham JL, Buyske S, Demirkan A, Ehret GB, Feitosa MF, Goel A, Jackson AU, Johnson T, Kleber ME, Kristiansson K, Mangino M, Mateo Leach I, Medina-Gomez C, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Stančáková A, Ju Sung Y, Tanaka T, Teumer A, Van Vliet-Ostaptchouk JV, Yengo L, Zhang W, Albrecht E, Ärnlöv J, Arscott GM, Bandinelli S, Barrett A, Bellis C, Bennett AJ, Berne C, Blüher M, Böhringer S, Bonnet F, Böttcher Y, Bruinenberg M, Carba DB, Caspersen IH, Clarke R, Warwick Daw E, Deelen J, Deelman E, Delgado G, Doney ASF, Eklund N, Erdos MR, Estrada K, Eury E, Friedrich N, Garcia ME, Giedraitis V, Gigante B, Go AS, Golay A, Grallert H, Grammer TB, Gräßler J, Grewal J, Groves CJ, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward C, Heikkilä K, Herzig K-H, Helmer Q, Hillege HL, Holmen O, Hunt SC, Isaacs A, Ittermann T, James AL, Johansson I, Juliusdottir T, Kalafati I-P, Kinnunen L, Koenig W, Kooner IK, Kratzer W, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindström J, Lobbens S, Lorentzon M, Mach F, Magnusson PKE, Mahajan A, McArdle WL, Menni C, Merger S, Mihailov E, Milani L, Mills R, Moayyeri A, Monda KL, Mooijaart SP, Mühleisen TW, Mulas A, Müller G, Müller-Nurasyid M, Nagaraja R, Nalls MA, Narisu N, Glorioso N, Nolte IM, Olden M, Rayner NW, Renstrom F, Ried JS, Robertson NR, Rose LM, Sanna S, Scharnagl H, Scholtens S, Sennblad B, Seufferlein T, Sitlani CM, Vernon Smith A, Stirrups K, Stringham HM, Sundström J, Swertz MA, Swift AJ, Syvänen A-C, Tayo BO, Thorand B, Thorleifsson G, Tomaschitz A, Troffa C, van Oort FVA, Verweij N, Vonk JM, Waite LL, Wennauer R, Wilsaard T, Wojczynski MK, Wong A, Zhang Q, Hua Zhao J, Brennan EP, Choi M, Eriksson P, Folkersen L, Franco-Cereceda A, Gharavi AG, Hedman AK, Hivert M-F, Huang J, Kanoni S, Karpe F, Keildson S, Kiryluk K, Liang L, Lifton RP, Ma B, McKnight AJ, McPherson R, Metspalu A, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Olsson C, Perry JRB, Reinmaa E, Salem RM, Sandholm N, Schadt EE, Scott RA, Stolk L, Vallejo EE, Westra H-J, Zondervan KT, Amouyel P, Arveiler D, Bakker SJL, Beilby J, Bergman RN, Blangero J, Brown J, Burnier M, Campbell H, Chakravarti A, Chines PS, Claudi-Boehm S, Collins FS, Crawford DC, Danesh J, de Faire U, de Geus EJC, Dörner M, Erbel R, Eriksson JG, Farrall M, Ferrannini E, Ferrières J, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gieger C, Gudnason V, Haiman CA, Harris TB, Hattersley AT, Heliövaara M, Hicks AA, Hingorani AD, Hoffmann W, Hofman A, Homuth G, Humphries SE, Hyppönen E, Illig T, Jarvelin M-R, Johansen B, Jousilahti P, Julia AM, Kaprio J, Kee F, Keinänen-Kiukkaanniemi SM, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuulasmaa K, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimäki T, Lyssenko V, Männistö S, Marette A, Matise TC, McKenzie CA, McKnight B, Musk AW, Möhlenkamp S, Morris AD, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Palmer LJ, Penninx BW, Peters A, Pramstaller PP, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schwarz PEH, Shuldiner AR, Staessen JA, Steinthorsdottir V, Stolk RP, Strauch K, Tönjes A, Tremblay A, Tremoli E, Vohl M-C, Völker U, Vollenweider P, Wilson JF, Witteman JC, Adair LS, Bochud M, Boehm BO, Bornstein SR, Bouchard C, Cauchi S, Caulfield MJ, Chambers JC, Chasman DI, Cooper RS, Dedoussis G, Ferrucci L, Froguel P, Grabe H-J, Hamsten A, Hui J, Hveem K, Jöckel K-H, Kivimäki M, Kuh D, Laakso M, Liu Y, März W, Munroe PB, Njølstad I, Oostra BA, Palmer CNA, Pedersen NL, Perola M, Pérusse L, Peters U, Power C, Quertemous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sinisalo J, Eline Slagboom P, Snieder H, Spector TD, Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Veronesi G, Walker M, Wareham NJ, Watkins H, Wichmann H-E, Abecasis GR, Assimes TL, Berndt SI, Boehnke M, Borecki IB, Deloukas P, Franke L, Frayling TM, Groop LC, Hunter DJ, Kaplan RC, O'Connell JR, Qi L, Schlessinger D, Strachan DP, Stefansson K, van Duijn CM, Willer CJ, Visscher PM, Yang J, Hirschhorn JN, Carola Zillikens M, McCarthy MI, Speliotes EK, North KE, Fox CS, Barroso I, Franks PW, Ingelsson E, Heid IM, Loos RJF, Cupples LA, Morris AP, Lindgren CM, Mohlke KL, McCarthy MI, Speliotes EK, North KE, Fox CS, Barroso I, Franks PW, Ingelsson E, Heid IM, Loos RJF, Cupples LA, Morris AP, Lindgren CM, Mohlke KL. New genetic loci link adipose and insulin biology to body fat distribution. *Nature*. 2015;518:187–196.
32. Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, Voros S, Giugliano RP, Davey Smith G, Fazio S, Sabatine MS. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. *N Engl J Med*. 2016;375:2144–2153.
33. Rothman KJ. No adjustments are needed for multiple comparisons. *Epidemiology*. 1990;1:43–46.
34. Hamer M, O'Donovan G. Sarcopenic obesity, weight loss, and mortality: the English Longitudinal Study of Ageing. *Am J Clin Nutr*. 2017;ajcn152488.
35. Stenholm S, Mehta NK, Elo IT, Heliövaara M, Koskinen S, Aromaa A. Obesity and muscle strength as long-term determinants of all-cause mortality—a 33-year follow-up of the Mini-Finland Health Examination Survey. *Int J Obes (Lond)*. 2014;38:1126–1132.
36. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, Allen NE. Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population. *Am J Epidemiol*. 2017;186:1026–1034.
37. Stephen WC, Janssen I. Sarcopenic-obesity and cardiovascular disease risk in the elderly. *J Nutr Health Aging*. 2009;13:460–466.
38. Flamm SD, Taki J, Moore R, Lewis SF, Keech F, Maltais F, Ahmad M, Callahan R, Dragotakes S, Alpert N. Redistribution of regional and organ blood volume and effect on cardiac function in relation to upright exercise intensity in healthy human subjects. *Circulation*. 1990;81:1550–1559.
39. Bowden J, Dudbridge F. Unbiased estimation of odds ratios: combining genome-wide association scans with replication studies. *Genet Epidemiol*. 2009;33:406–418.

SUPPLEMENTAL MATERIAL

Table S1. Genetic Quality Control (QC) details.

Level	QC operation	Notes
Individual	Sex mismatch	Drop patients with a mismatch between genetic sex and self-reported sex at baseline
Individual	Recommended UK BeLIVE exclusions	Recommended by UK Biobank for the 50,005 patients genotyped using UK BeLIVE.
Individual	Recommend exclusion	Recommended genomic exclusion for poor heterozygosity/missingness
Individual	Genetic relatedness	Kinship coefficient 0.044 – remove all related individuals
Individual	Population origin	Drop non-CEU participants
Individual	Heterozygosity	Filter out samples with heterozygosity (as taken from the "heterozygosity" column of the sample file, which must be present) outside the interval [0.18,0.2]
Individual	Sample-missing-rate	Filter out samples with missing data rate (as taken from the "missing" column of the sample file) greater than 5%
SNP [‡]	Information score	Filter out SNPs with Fisher information < 0.3
SNP	SNP missing call rate	Filter out SNPs with missing call rate greater than or equal 5%
SNP	Hardy-Weinberg Equilibrium	HWE threshold $-\log_{10}(\text{p-value}) \leq 1 \times 10^{-6}$
SNP	Minor Allele Frequency	MAF outside 0.01-1 range
SNP	SNP missing rate	Filter out SNPs with missing data rate greater than or equal to 5%

Table S2. Waist hip ratio SNPs identified from previous study, and internal/external weights used for MR analyses.

Waist Hip Ratio					
Rsid	Effect Allele	MAF internal	Internal Weight	MAF external	External Weight
Included in Genetic Risk Score					
rs10195252	T	0.594	0.122	0.558	0.027
rs10245353	A	0.176	0.206	0.183	0.035
rs1045241	C	0.742	0.058	0.692	0.019
rs10804591	A	0.790	0.138	0.850	0.024
rs10842707	T	0.208	0.179	0.167	0.032
rs10919388	C	0.761	0.196	0.717	0.024
rs10991437	A	0.117	0.248	0.100	0.031
rs11231693	A	0.049	0.226	0.042	0.041
rs12454712	T	0.624	0.053	0.633	0.016
rs12608504	A	0.365	0.127	0.342	0.022
rs12679556	G	0.235	0.108	0.208	0.027
rs1294410	C	0.622	0.171	0.625	0.031
rs1358980	T	0.460	0.197	0.450	0.039
rs1385167	G	0.123	0.078	0.142	0.029
rs1440372	C	0.751	0.068	0.742	0.024
rs1443512	A	0.217	0.200	0.200	0.028
rs1534696	C	0.461	0.165	0.350	0.011
rs1569135	A	0.552	0.234	0.533	0.021
rs1776897	G	0.089	0.232	0.075	0.03
rs17819328	G	0.418	0.184	0.450	0.021
rs1936805	T	0.519	0.226	0.550	0.042
rs224333	G	0.642	0.011	0.667	0.02
rs2276824	C	0.439	0.099	0.483	0.024
rs2294239	A	0.572	0.146	0.550	0.025
rs2371767	G	0.738	0.248	0.792	0.036
rs2645294	T	0.571	0.209	0.535	0.031
rs2820443	T	0.704	0.214	0.700	0.035
rs2925979	T	0.301	0.149	0.283	0.018
rs303084	A	0.794	0.150	0.783	0.023
rs3805389	A	0.243	0.049	0.242	0.012
rs4081724	G	0.870	0.126	0.850	0.035
rs4646404	G	0.670	0.129	0.625	0.027
rs4765219	C	0.667	0.185	0.625	0.028
rs6556301	T	0.357	0.146	0.375	0.022
rs714515	G	0.436	0.193	0.458	0.027
rs7705502	A	0.298	0.037	0.292	0.027
rs7830933	A	0.776	0.091	0.742	0.022
rs7917772	A	0.632	0.046	0.683	0.014
rs8030605	A	0.124	0.004	0.158	0.03
rs8066985	A	0.485	0.126	0.517	0.018
rs905938	T	0.733	0.101	0.675	0.025
rs9687846	A	0.201	0.167	0.192	0.024
rs979012	T	0.365	0.085	0.358	0.027

rs9991328	T	0.458	0.113	0.483	0.018
Excluded SNPs that did not pass the overall QC in our data processing step					
rs17451107					
rs6090583					
rs7759742					
rs7801581					
rs8042543					

Table S3. BMI SNPs and internal/external weights used for MR analyses.

BMI					
Rsid	Effect Allele	MAF internal	Internal Weight	MAF external	External Weight
Included in Genetic Risk Score					
rs1000940	G	0.30	0.060	0.225	0.019
rs10132280	C	0.72	0.085	0.667	0.023
rs1016287	T	0.30	0.102	0.325	0.023
rs10182181	G	0.49	0.159	0.500	0.031
rs10938397	G	0.43	0.134	0.433	0.040
rs10968576	G	0.32	0.119	0.292	0.025
rs11030104	A	0.80	0.204	0.800	0.041
rs11057405	G	0.89	0.132	0.908	0.031
rs11126666	A	0.25	0.004	0.308	0.021
rs11165643	T	0.60	0.073	0.575	0.022
rs11191560	C	0.08	0.147	0.058	0.031
rs11583200	C	0.40	0.091	0.375	0.018
rs1167827	G	0.57	0.111	0.542	0.020
rs11688816	G	0.56	0.060	0.458	0.017
rs11727676	T	0.90	0.020	0.925	0.036
rs11847697	T	0.04	0.057	0.042	0.049
rs12286929	G	0.52	0.035	0.433	0.022
rs12401738	A	0.37	0.065	0.425	0.021
rs12429545	A	0.12	0.124	0.100	0.033
rs12446632	G	0.86	0.107	0.867	0.040
rs12566985	G	0.43	0.052	0.425	0.024
rs12885454	C	0.65	0.077	0.633	0.021
rs12940622	G	0.56	0.093	0.542	0.018
rs13021737	G	0.84	0.295	0.875	0.060
rs13078960	G	0.20	0.097	0.183	0.030
rs13107325	T	0.07	0.209	0.117	0.048
rs13191362	A	0.88	0.130	0.800	0.028
rs13201877	G	0.10	0.038	0.083	0.023
rs1441264	A	0.61	0.079	0.550	0.018
rs1460676	C	0.15	0.079	0.217	0.020
rs1516725	C	0.87	0.158	0.908	0.045
rs1528435	T	0.63	0.072	0.583	0.018
rs1558902	A	0.40	0.384	0.450	0.082
rs16851483	T	0.07	0.141	0.092	0.048
rs16907751	C	0.92	0.116	0.958	0.035
rs16951275	T	0.77	0.163	0.775	0.031
rs17024393	C	0.02	0.384	0.042	0.066
rs17094222	C	0.18	0.075	0.208	0.025
rs17203016	G	0.18	0.080	0.200	0.021
rs17405819	T	0.70	0.073	0.633	0.022
rs17724992	A	0.76	0.112	0.692	0.019
rs1808579	C	0.51	0.104	0.525	0.017

rs1928295	T	0.57	0.051	0.575	0.019
rs2033732	C	0.74	0.016	0.758	0.019
rs205262	G	0.26	0.143	0.267	0.022
rs2080454	C	0.39	0.068	0.392	0.017
rs2112347	T	0.64	0.121	0.625	0.026
rs2121279	T	0.12	0.017	0.117	0.025
rs2176040	A	0.35	0.043	0.392	0.014
rs2176598	T	0.25	0.117	0.200	0.020
rs2207139	G	0.17	0.203	0.100	0.045
rs2287019	C	0.84	0.180	0.850	0.036
rs2365389	C	0.59	0.135	0.658	0.020
rs2650492	A	0.27	0.001	0.308	0.021
rs2820292	C	0.57	0.101	0.508	0.020
rs2836754	C	0.64	0.062	0.650	0.016
rs29941	G	0.67	0.090	0.667	0.018
rs3101336	C	0.60	0.129	0.649	0.033
rs3736485	A	0.46	0.057	0.425	0.018
rs3810291	A	0.68	0.135	0.625	0.028
rs3817334	T	0.41	0.143	0.450	0.026
rs3849570	A	0.32	0.032	0.367	0.019
rs3888190	A	0.41	0.111	0.358	0.031
rs4256980	G	0.66	0.103	0.725	0.021
rs4740619	T	0.55	0.067	0.533	0.018
rs4787491	G	0.55	0.095	0.614	0.016
rs492400	C	0.43	0.016	0.325	0.016
rs543874	G	0.21	0.237	0.267	0.048
rs6091540	C	0.73	0.094	0.725	0.019
rs6465468	T	0.27	0.005	0.325	0.017
rs6477694	C	0.35	0.025	0.358	0.017
rs6567160	C	0.23	0.235	0.283	0.056
rs657452	A	0.40	0.002	0.417	0.023
rs6804842	G	0.56	0.058	0.575	0.019
rs7138803	A	0.37	0.162	0.442	0.032
rs7141420	T	0.52	0.091	0.617	0.024
rs7164727	T	0.67	0.108	0.775	0.018
rs7239883	G	0.38	0.063	0.317	0.016
rs7243357	T	0.84	0.066	0.867	0.022
rs758747	T	0.25	0.079	0.267	0.023
rs7599312	G	0.76	0.093	0.708	0.022
rs7715256	G	0.43	0.072	0.450	0.016
rs7899106	G	0.05	0.090	0.050	0.040
rs7903146	C	0.71	0.130	0.750	0.023
rs9374842	T	0.78	0.057	0.742	0.019
rs9400239	C	0.71	0.082	0.700	0.019
rs9540493	A	0.47	0.068	0.450	0.017
rs9641123	C	0.40	0.054	0.392	0.019
rs977747	T	0.42	0.087	0.467	0.017
rs9914578	G	0.20	0.030	0.167	0.020

Excluded SNPs that did not pass the overall QC in our data processing step					
rs10733682					
rs12016871					
rs17001654					
rs2033529					
rs2075650					
rs9925964					

Table S4. Hand grip strength SNPs and internal/external weights used for MR analyses.

Hand Grip Strength					
Rsid	Effect Allele	MAF internal	Internal Weight	MAF external	External Weight
Included in Genetic Risk Score					
rs10186876	A	0.353	0.102	0.360	0.113
rs10861798	A	0.429	0.225	0.430	0.159
rs2110927	C	0.261	0.130	0.270	0.098
rs2273555	A	0.607	0.169	0.610	0.096
rs2288278	A	0.658	0.150	0.660	0.147
rs374532236	T	0.357	0.185	0.380	0.121
rs4926611	C	0.643	0.117	0.640	0.115
rs6565586	A	0.243	0.190	0.250	0.096
rs6687430	G	0.459	0.166	0.460	0.125
rs72762373	A	0.019	0.681	0.030	0.359
rs72979233	A	0.756	0.185	0.760	0.112
rs958685	A	0.516	0.143	0.520	0.164
Excluded SNPs that did not pass the overall QC in our data processing step					
rs11614333					
rs34845616					
rs78325334					
rs80103986					

Table S5. Adjusted* hazard (with 95% confidence interval) ratios of combined fatal/non CHD events and mortality by quintiles of BMI and HGS for those without history of CVD.

Fatal/non-fatal CHD						
HGS Quintile (kg)						
	43-90	35-42	29-34	23-28	0-22	P value for interaction
BMI Quintile (kg/m ²)	12-23	1 (ref)	0.84 (0.59 , 1.19)	1.01 (0.71 , 1.43)	1.02 (0.71 , 1.47)	1.64 (1.18 , 2.29)
	23-26	1.15 (0.84 , 1.57)	1.28 (0.94 , 1.73)	1.34 (0.97 , 1.85)	1.78 (1.28 , 2.48)	1.57 (1.12 , 2.21)
	26-28	1.47 (1.09 , 1.97)	1.51 (1.12 , 2.02)	1.7 (1.25 , 2.31)	1.69 (1.21 , 2.36)	1.89 (1.36 , 2.64)
	28-31	1.47 (1.1 , 1.98)	1.6 (1.2 , 2.15)	1.81 (1.33 , 2.46)	1.88 (1.35 , 2.61)	2.21 (1.59 , 3.05)
	31-60	2.32 (1.74 , 3.09)	1.76 (1.31 , 2.37)	2.41 (1.78 , 3.26)	2.36 (1.72 , 3.25)	2.59 (1.89 , 3.54)
						0.101
CHD Mortality						
HGS Quintile (kg)						
	43-90	35-42	29-34	23-28	0-22	P value for interaction
BMI Quintile (kg/m ²)	12-23	1 (ref)	0.94 (0.5 , 1.8)	1.18 (0.6 , 2.32)	1.49 (0.72 , 3.08)	3.44 (1.82 , 6.51)
	23-26	0.97 (0.52 , 1.8)	1.13 (0.63 , 2.04)	1.4 (0.74 , 2.64)	2.72 (1.44 , 5.12)	3.09 (1.61 , 5.93)
	26-28	1.17 (0.66 , 2.08)	1.38 (0.78 , 2.43)	1.4 (0.75 , 2.61)	1.44 (0.7 , 2.97)	3.64 (1.93 , 6.87)
	28-31	1.4 (0.8 , 2.46)	1.33 (0.75 , 2.34)	1.73 (0.95 , 3.15)	2.6 (1.39 , 4.86)	3.12 (1.64 , 5.94)
	31-60	1.75 (1 , 3.08)	1.77 (1.01 , 3.11)	2.49 (1.4 , 4.43)	2.7 (1.43 , 5.08)	2.73 (1.44 , 5.17)
						0.342

*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and deprivation. BMI – body mass index HGS – hand grip strength

Table S6. Adjusted* hazard (with 95% confidence interval) ratios of combined fatal/non CHD events and mortality by quintiles of BMI and HGS for those with history of CVD.

Fatal/non-fatal CHD							
BMI Quintile (kg/m2)	HGS Quintile (kg)					P value for interaction	
	43-90	35-42	29-34	23-28	0-22		
	12-23	1 (ref)	1.24 (0.82 , 1.87)	1.16 (0.76 , 1.77)	0.97 (0.62 , 1.52)	1.46 (0.98 , 2.19)	0.455
	23-26	1.45 (0.98 , 2.15)	1.77 (1.22 , 2.58)	1.88 (1.28 , 2.76)	1.41 (0.93 , 2.13)	1.73 (1.16 , 2.57)	
	26-28	1.78 (1.23 , 2.59)	1.8 (1.25 , 2.6)	1.8 (1.24 , 2.62)	1.98 (1.34 , 2.93)	2 (1.36 , 2.94)	
	28-31	1.84 (1.28 , 2.65)	1.92 (1.34 , 2.76)	1.68 (1.16 , 2.45)	1.76 (1.2 , 2.6)	2.18 (1.49 , 3.18)	
	31-60	2.47 (1.73 , 3.54)	2.24 (1.57 , 3.21)	2.29 (1.59 , 3.29)	2.3 (1.58 , 3.33)	2.81 (1.95 , 4.05)	
	CHD Mortality						
	HGS Quintile (kg)					P value for interaction	
	43-90	35-42	29-34	23-28	0-22		
	12-23	1 (ref)	1.83 (0.6 , 5.56)	2.32 (0.77 , 7)	4.32 (1.45 , 12.84)	4.23 (1.44 , 12.49)	0.745
	23-26	2.07 (0.7 , 6.09)	2.28 (0.81 , 6.45)	2.84 (0.99 , 8.19)	2.66 (0.88 , 8.07)	3.98 (1.35 , 11.73)	
	26-28	2.03 (0.71 , 5.78)	2.09 (0.75 , 5.83)	3.05 (1.09 , 8.55)	4.05 (1.41 , 11.62)	3.06 (1.04 , 9)	
	28-31	1.62 (0.57 , 4.6)	2.45 (0.89 , 6.74)	2.68 (0.96 , 7.45)	2.8 (0.97 , 8.06)	2.81 (0.97 , 8.15)	
	31-60	2.49 (0.9 , 6.87)	2.99 (1.1 , 8.15)	3.17 (1.15 , 8.7)	3.46 (1.24 , 9.67)	4.21 (1.51 , 11.69)	

*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and deprivation. BMI – body mass index HGS – hand grip strength

Table S7. Distribution of Obesity and Sarcopenia at baseline by sex.

	Overall		Male		Female	
BMI and grip Strength	N	%	N	%	N	%
Non-Obese/Non-Sarcopenic	296,567	65.5%	140,302	68.3%	156,265	63.2%
Obese	89,906	19.8%	45,979	22.4%	43,927	17.8%
Sarcopenic	48,250	10.7%	13,820	6.7%	34,430	13.9%
Sarcopenic Obesity	18,208	4.0%	5,467	2.7%	12,741	5.2%
BMI and SMMI	N	%	N	%	N	%
Non-Obese/Non-Sarcopenic	170,532	38.1%	75,449	37.2%	95,083	38.9%
Obese	96,354	21.5%	45,824	22.6%	50,530	20.6%
Sarcopenic	170,428	38.1%	76,764	37.8%	93,664	38.3%
Sarcopenic Obesity	10,247	2.3%	4,790	2.4%	5,457	2.2%
WHR and grip Strength	N	%	N	%	N	%
Non-Obese/Non-Sarcopenic	206,533	45.5%	115,795	56.2%	90,738	36.6%
Obese	182,592	40.2%	71,634	34.8%	110,958	44.8%
Sarcopenic	23,714	5.2%	8,402	4.1%	15,312	6.2%
Sarcopenic Obesity	40,842	9.0%	10,187	4.9%	30,655	12.4%
WHR and SMMI	N	%	N	%	N	%
Non-Obese/Non-Sarcopenic	125,213	28.0%	68,397	33.7%	56,816	23.2%
Obese	144,608	32.3%	54,738	27.0%	89,870	36.7%
Sarcopenic	102,360	22.9%	54,227	26.7%	48,133	19.7%
Sarcopenic Obesity	75,308	16.8%	25,420	12.5%	49,888	20.4%

WHR – waist hip ratio, BMI – body mass index HGS – hand grip strength SMMI – skeletal muscle mass index

Table S8. Adjusted* hazard (with 95% confidence interval) ratios of all-cause and CVD mortality, and combined fatal/non CVD events by quintiles of BMI and SMMI in those without with a history of CVD.

		All-cause mortality						
		SMMI Quintile						
		9.2-31.2	8.3-9.2	7.0-8.3	6.3-7.0	4.2-6.3	P value for interaction	
BMI Quintile (kg/m2)	12-23	1 (ref)	0.8 (0.58 , 1.1)	1 (0.73 , 1.36)	1.02 (0.73 , 1.43)	0.87 (0.63 , 1.21)	0.061	
	23-26	0.80 (0.57 , 1.13)	0.74 (0.55 , 1.01)	0.90 (0.66 , 1.23)	0.80 (0.57 , 1.12)	0.86 (0.62 , 1.19)		
	26-28	0.72 (0.52 , 0.99)	0.76 (0.56 , 1.03)	0.96 (0.69 , 1.32)	0.82 (0.58 , 1.15)	0.81 (0.58 , 1.14)		
	28-31	0.84 (0.62 , 1.13)	0.86 (0.63 , 1.17)	0.92 (0.66 , 1.28)	0.79 (0.56 , 1.11)	0.95 (0.67 , 1.34)		
	31-60	0.97 (0.71 , 1.30)	0.99 (0.72 , 1.36)	0.92 (0.66 , 1.27)	0.88 (0.62 , 1.24)	0.97 (0.65 , 1.44)		
	Fatal/non-fatal CVD							
			SMMI Quintile					
			9.2-31.2	8.3-9.2	7.0-8.3	6.3-7.0	4.2-6.3	P value for interaction
		12-23	1 (ref)	1.28 (0.92 , 1.78)	1.36 (0.98 , 1.88)	1.31 (0.93 , 1.84)	1.20 (0.86 , 1.68)	0.004
		23-26	1.43 (1.02 , 2.01)	1.35 (0.98 , 1.87)	1.19 (0.86 , 1.65)	1.28 (0.91 , 1.81)	1.42 (1.02 , 1.99)	
26-28		1.38 (1.00 , 1.91)	1.47 (1.07 , 2.02)	1.68 (1.21 , 2.34)	1.32 (0.94 , 1.86)	1.37 (0.97 , 1.92)		
28-31		1.60 (1.17 , 2.20)	1.51 (1.09 , 2.08)	1.65 (1.18 , 2.31)	1.47 (1.04 , 2.06)	1.54 (1.09 , 2.19)		
31-60		2.00 (1.46 , 2.74)	1.92 (1.38 , 2.66)	1.83 (1.32 , 2.56)	1.61 (1.14 , 2.27)	1.93 (1.32 , 2.82)		
Fatal CVD								
		SMMI Quintile						
		9.2-31.2	8.3-9.2	7.0-8.3	6.3-7.0	4.2-6.3	P value for interaction	
	12-23	1 (ref)	1.49 (0.64 , 3.45)	1.85 (0.81 , 4.23)	1.77 (0.73 , 4.34)	1.37 (0.57 , 3.27)	0.297	
	23-26	1.44 (0.6 , 3.45)	1.43 (0.63 , 3.25)	1.56 (0.68 , 3.6)	1.43 (0.58 , 3.53)	1.86 (0.78 , 4.47)		
	26-28	1.27 (0.55 , 2.93)	1.4 (0.62 , 3.19)	1.61 (0.69 , 3.77)	1.32 (0.53 , 3.25)	1.32 (0.54 , 3.27)		
	28-31	1.78 (0.79 , 4.02)	1.62 (0.71 , 3.68)	2.1 (0.89 , 4.96)	1.37 (0.56 , 3.37)	2.22 (0.9 , 5.45)		
	31-60	2.34 (1.04 , 5.27)	1.91 (0.82 , 4.44)	2.32 (0.98 , 5.5)	1.4 (0.56 , 3.5)	1.68 (0.6 , 4.71)		

*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and deprivation BMI- body mass index. SMMI – skeletal muscle mass index

Table S9. Adjusted* hazard (with 95% confidence interval) ratios of all-cause and CVD mortality, and combined fatal/non CVD events by quintiles of BMI and SMMI in those with a history of CVD.

	All-cause mortality						
	SMMI Quintile					P value for interaction	
	9.2-31.2	8.3-9.2	7.0-8.3	6.3-7.0	4.2-6.3		
	12-23	23-26	26-28	28-31	31-60		
	1 (ref)	0.66 (0.36 , 1.24)	0.93 (0.51 , 1.68)	1.24 (0.65 , 2.36)	1.06 (0.57 , 1.97)		
	0.83 (0.44 , 1.56)	0.69 (0.38 , 1.25)	0.85 (0.47 , 1.54)	0.72 (0.37 , 1.4)	0.65 (0.34 , 1.23)	0.012	
	0.69 (0.38 , 1.25)	0.65 (0.36 , 1.17)	0.91 (0.5 , 1.65)	0.72 (0.37 , 1.38)	0.65 (0.34 , 1.25)		
	0.65 (0.36 , 1.16)	0.77 (0.43 , 1.37)	0.63 (0.34 , 1.17)	0.7 (0.37 , 1.33)	0.54 (0.27 , 1.07)		
	0.79 (0.45 , 1.41)	0.9 (0.5 , 1.61)	0.9 (0.49 , 1.67)	0.79 (0.42 , 1.5)	0.76 (0.36 , 1.57)		
BMI Quintile (kg/m2)	Fatal/non-fatal CVD						
	SMMI Quintile					P value for interaction	
	9.2-31.2	8.3-9.2	7.0-8.3	6.3-7.0	4.2-6.3		
	12-23	23-26	26-28	28-31	31-60		
		1 (ref)	0.79 (0.49 , 1.27)	0.93 (0.59 , 1.48)	0.89 (0.54 , 1.46)		0.93 (0.58 , 1.48)
		1.08 (0.67 , 1.75)	0.9 (0.57 , 1.41)	1.12 (0.71 , 1.76)	0.97 (0.6 , 1.58)	0.96 (0.59 , 1.54)	
		1.06 (0.67 , 1.68)	1.02 (0.65 , 1.59)	1.17 (0.74 , 1.84)	0.84 (0.52 , 1.36)	1.02 (0.63 , 1.64)	
		1.02 (0.66 , 1.6)	1.04 (0.67 , 1.63)	1.17 (0.74 , 1.87)	1.02 (0.63 , 1.64)	0.94 (0.58 , 1.54)	
		1.37 (0.88 , 2.13)	1.13 (0.72 , 1.78)	1.23 (0.77 , 1.96)	1.17 (0.73 , 1.88)	1.09 (0.64 , 1.84)	
	Fatal CVD						
SMMI Quintile					P value for interaction		
9.2-31.2	8.3-9.2	7.0-8.3	6.3-7.0	4.2-6.3			
12-23	23-26	26-28	28-31	31-60			
	1 (ref)	0.34 (0.16 , 0.74)	0.53 (0.26 , 1.07)	0.42 (0.17 , 1.02)		0.53 (0.24 , 1.14)	0.05
	0.43 (0.2 , 0.96)	0.40 (0.20 , 0.80)	0.5 (0.25 , 1.02)	0.36 (0.15 , 0.86)	0.27 (0.11 , 0.63)		
	0.42 (0.2 , 0.85)	0.40 (0.20 , 0.8)0	0.55 (0.27 , 1.13)	0.3 (0.12 , 0.72)	0.32 (0.14 , 0.74)		
	0.4 (0.2 , 0.79)	0.45 (0.23 , 0.89)	0.41 (0.19 , 0.86)	0.39 (0.17 , 0.89)	0.2 (0.08 , 0.53)		
	0.58 (0.29 , 1.12)	0.59 (0.30 , 1.18)	0.4 (0.19 , 0.86)	0.4 (0.18 , 0.9)	0.3 (0.1 , 0.88)		

*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and deprivation BMI- body mass index. SMMI – skeletal muscle mass index

Table S10. Adjusted* hazard (with 95% confidence interval) ratios of all-cause and CVD mortality, and combined fatal/non CVD events by quintiles of WHR and HGS in participants without history of CVD.

WHR Quintile	All-cause mortality						
	HGS Quintile (kg)					P value for interaction	
	43-90	35-42	29-34	23-28	0-22		
	0.44-0.79	1 (ref)	1.01 (0.56 , 1.83)	1.02 (0.59 , 1.76)	1.18 (0.69 , 2.02)		1.29 (0.76 , 2.21)
	0.79-0.85	0.66 (0.37 , 1.17)	0.71 (0.40 , 1.24)	1.10 (0.64 , 1.90)	1.18 (0.69 , 2.02)		1.48 (0.87 , 2.53)
0.85-0.90	0.77 (0.45 , 1.32)	0.90 (0.53 , 1.54)	1.11 (0.65 , 1.91)	1.22 (0.71 , 2.09)	1.47 (0.86 , 2.51)	0.138	
0.90-0.95	0.78 (0.46 , 1.33)	1.03 (0.60 , 1.75)	1.17 (0.68 , 1.99)	1.33 (0.77 , 2.28)	1.63 (0.95 , 2.80)		
0.95-1.30	1.13 (0.67 , 1.92)	1.17 (0.69 , 2.00)	1.47 (0.86 , 2.49)	1.70 (0.99 , 2.90)	1.77 (1.03 , 3.05)		
Fatal/non-fatal CVD							
WHR Quintile	HGS Quintile (kg)					P value for interaction	
	43-90	35-42	29-34	23-28	0-22		
	0.44-0.79	1 (ref)	1.33 (0.79 , 2.23)	1.24 (0.76 , 2.02)	1.17 (0.72 , 1.90)		1.18 (0.72 , 1.92)
	0.79-0.85	1.42 (0.86 , 2.34)	1.32 (0.80 , 2.16)	1.45 (0.89 , 2.36)	1.41 (0.87 , 2.29)		1.37 (0.84 , 2.23)
	0.85-0.90	1.34 (0.83 , 2.18)	1.29 (0.79 , 2.09)	1.46 (0.90 , 2.38)	1.49 (0.92 , 2.43)	1.52 (0.93 , 2.47)	0.500
	0.90-0.95	1.55 (0.96 , 2.50)	1.60 (0.99 , 2.59)	1.56 (0.96 , 2.54)	1.47 (0.90 , 2.40)	1.63 (1.00 , 2.66)	
	0.95-1.30	1.86 (1.15 , 3.00)	1.69 (1.04 , 2.72)	1.89 (1.16 , 3.06)	1.87 (1.15 , 3.05)	1.88 (1.15 , 3.07)	
Fatal CVD							
WHR Quintile	HGS Quintile (kg)					P value for interaction	
	43-90	35-42	29-34	23-28	0-22		
	0.44-0.79	1 (ref)	1.41 (0.40 , 5.02)	0.76 (0.22 , 2.57)	1.06 (0.33 , 3.44)		1.13 (0.35 , 3.65)
	0.79-0.85	0.81 (0.24 , 2.75)	0.68 (0.20 , 2.32)	1.21 (0.37 , 3.95)	1.29 (0.40 , 4.17)		1.83 (0.57 , 5.84)
	0.85-0.90	0.83 (0.26 , 2.64)	0.83 (0.26 , 2.66)	1.12 (0.35 , 3.60)	1.22 (0.38 , 3.93)	1.69 (0.53 , 5.42)	0.418
	0.90-0.95	0.84 (0.26 , 2.64)	1.14 (0.36 , 3.58)	1.22 (0.38 , 3.87)	1.74 (0.54 , 5.57)	1.92 (0.60 , 6.17)	
	0.95-1.30	1.30 (0.41 , 4.07)	1.31 (0.42 , 4.10)	1.78 (0.57 , 5.58)	2.16 (0.68 , 6.85)	2.32 (0.73 , 7.39)	

*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and deprivation. WHR- waist hip ratio. HGS – hand grip strength

Table S11. Adjusted* hazard (with 95% confidence interval) ratios of all-cause and CVD mortality, and combined fatal/non CVD events by quintiles of WHR and HGS in participants with history of CVD.

		All-cause mortality						
		HGS Quintile (kg)						
		43-90	35-42	29-34	23-28	0-22	P value for interaction	
WHR Quintile	0.44-0.79	1 (ref)	1.73 (0.38 , 7.91)	1.26 (0.3 , 5.34)	1.63 (0.4 , 6.73)	1.6 (0.39 , 6.55)	0.911	
	0.79-0.85	0.98 (0.23 , 4.28)	1.35 (0.32 , 5.64)	1.33 (0.32 , 5.49)	1.77 (0.43 , 7.22)	2.14 (0.53 , 8.68)		
	0.85-0.90	1.09 (0.27 , 4.45)	1.23 (0.3 , 5.01)	1.6 (0.39 , 6.51)	1.86 (0.45 , 7.58)	2.05 (0.51 , 8.34)		
	0.90-0.95	1.1 (0.27 , 4.47)	1.26 (0.31 , 5.1)	1.7 (0.42 , 6.88)	1.89 (0.47 , 7.68)	2.31 (0.57 , 9.35)		
	0.95-1.30	1.49 (0.37 , 5.99)	1.59 (0.39 , 6.38)	1.81 (0.45 , 7.27)	2.28 (0.56 , 9.2)	2.75 (0.68 , 11.1)		
	Fatal/non-fatal CVD							
	HGS Quintile (kg)							
		43-90	35-42	29-34	23-28	0-22	P value for interaction	
WHR Quintile	0.44-0.79	1 (ref)	1.15 (0.51 , 2.62)	0.85 (0.39 , 1.83)	0.94 (0.44 , 2)	1.04 (0.49 , 2.21)	0.706	
	0.79-0.85	1.33 (0.61 , 2.9)	0.98 (0.45 , 2.13)	1.18 (0.55 , 2.52)	1.09 (0.51 , 2.32)	1.11 (0.52 , 2.35)		
	0.85-0.90	1.08 (0.51 , 2.3)	1.11 (0.52 , 2.36)	1.19 (0.56 , 2.54)	1.15 (0.54 , 2.44)	1.21 (0.57 , 2.57)		
	0.90-0.95	1.11 (0.53 , 2.34)	1.21 (0.57 , 2.55)	1.22 (0.58 , 2.58)	1.18 (0.55 , 2.51)	1.32 (0.62 , 2.81)		
	0.95-1.30	1.34 (0.63 , 2.81)	1.27 (0.6 , 2.68)	1.33 (0.63 , 2.81)	1.33 (0.63 , 2.81)	1.46 (0.69 , 3.09)		
	Fatal CVD							
	HGS Quintile (kg)							
		43-90	35-42	29-34	23-28	0-22	P value for interaction	
WHR Quintile	0.44-0.79	1 (ref)	2.03 (0.24 , 17.5)	0.81 (0.1 , 6.79)	1.07 (0.14 , 8.2)	1.35 (0.18 ,10.03)	0.418	
	0.79-0.85	0.35 (0.04 , 3.41)	1.15 (0.15 , 8.8)	1.42 (0.19 ,10.68)	1.76 (0.24 ,12.99)	1.83 (0.25 ,13.38)		
	0.85-0.90	0.81 (0.11 , 6.04)	1.09 (0.15 , 7.97)	1.39 (0.19 ,10.21)	1.66 (0.22 ,12.22)	1.53 (0.21 ,11.18)		
	0.90-0.95	0.79 (0.11 , 5.75)	1.16 (0.16 , 8.37)	1.36 (0.19 , 9.83)	1.49 (0.2 , 10.91)	2.04 (0.28 ,14.81)		
	0.95-1.30	1.24 (0.17 , 8.89)	1.43 (0.2 , 10.26)	1.65 (0.23 ,11.87)	2.14 (0.3 , 15.4)	2.61 (0.36 ,18.76)		

*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and deprivation. WHR- waist hip ratio. HGS – hand grip strength

Table S12. Adjusted* hazard (with 95% confidence interval) ratios of all-cause and CVD mortality, and combined fatal/non CVD events by quintiles of Fat mass (%) and HGS in participants without history of CVD.

		All-cause mortality					
		HGS Quintile (kg)					
		43-90	35-42	29-34	23-28	0-22	P value for interaction
Fat mass quintile (%)	5-23.8	1 (ref)	1.39 (1.23 , 1.58)	1.82 (1.57 , 2.10)	2.21 (1.84 , 2.65)	3.12 (2.57 , 3.78)	<0.001
	23.9-28.6	1.23 (1.08 , 1.41)	1.34 (1.17 , 1.52)	1.55 (1.34 , 1.80)	1.87 (1.58 , 2.23)	2.64 (2.21 , 3.16)	
	28.7-33.5	1.42 (1.23 , 1.65)	1.49 (1.29 , 1.71)	1.77 (1.53 , 2.06)	2.00 (1.70 , 2.35)	2.10 (1.78 , 2.48)	
	33.6-39.2	1.61 (1.29 , 2.01)	1.65 (1.37 , 1.99)	1.82 (1.54 , 2.15)	2.02 (1.73 , 2.36)	2.22 (1.90 , 2.59)	
	39.3-69.8	2.89 (1.88 , 4.45)	1.58 (1.17 , 2.14)	2.04 (1.70 , 2.44)	2.05 (1.75 , 2.41)	2.52 (2.16 , 2.93)	
	Fatal/non-fatal CVD						
		HGS Quintile (kg)					
		43-90	35-42	29-34	23-28	0-22	P value for interaction
Fat mass quintile (%)	5-23.8	1 (ref)	1.02 (0.93 , 1.13)	1.05 (0.93 , 1.19)	1.22 (1.03 , 1.43)	1.41 (1.17 , 1.70)	0.002
	23.9-28.6	1.23 (1.12 , 1.36)	1.09 (0.99 , 1.21)	1.22 (1.09 , 1.37)	1.11 (0.95 , 1.29)	1.21 (1.02 , 1.43)	
	28.7-33.5	1.26 (1.13 , 1.41)	1.24 (1.12 , 1.39)	1.25 (1.11 , 1.41)	1.31 (1.15 , 1.49)	1.22 (1.06 , 1.41)	
	33.6-39.2	1.64 (1.39 , 1.94)	1.46 (1.26 , 1.68)	1.51 (1.33 , 1.72)	1.45 (1.28 , 1.65)	1.30 (1.14 , 1.48)	
	39.3-69.8	1.44 (0.93 , 2.25)	1.64 (1.32 , 2.03)	1.78 (1.55 , 2.04)	1.60 (1.41 , 1.81)	1.77 (1.57 , 2.00)	
	Fatal CVD						
		HGS Quintile (kg)					
		43-90	35-42	29-34	23-28	0-22	P value for interaction
Fat mass quintile (%)	5-23.8	1 (ref)	1.32 (1.02 , 1.72)	1.64 (1.21 , 2.22)	2.84 (2 , 4.04)	3.67 (2.48 , 5.42)	0.050
	23.9-28.6	1.41 (1.08 , 1.83)	1.38 (1.06 , 1.81)	1.68 (1.25 , 2.26)	2.20 (1.54 , 3.13)	2.86 (1.93 , 4.22)	
	28.7-33.5	1.59 (1.18 , 2.13)	1.64 (1.24 , 2.17)	1.99 (1.47 , 2.7)	2.24 (1.58 , 3.17)	2.59 (1.81 , 3.71)	
	33.6-39.2	2.02 (1.34 , 3.05)	2.12 (1.49 , 3.02)	2.38 (1.69 , 3.37)	2.42 (1.71 , 3.44)	2.82 (2.02 , 3.95)	
	39.3-69.8	2.81 (1.14 , 6.9)	2.43 (1.32 , 4.46)	3.19 (2.17 , 4.7)	2.92 (2.05 , 4.17)	3.74 (2.70 , 5.17)	

*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and deprivation HGS – hand grip strength

Table S13. Adjusted* hazard (with 95% confidence interval) ratios of all-cause and CVD mortality, and combined fatal/non CVD events by quintiles of Fat mass (%) and HGS in participants with history of CVD.

		All-cause mortality					
		HGS Quintile (kg)					
		43-90	35-42	29-34	23-28	0-22	P value for interaction
Fat mass quintile (%)	5-23.8	1 (ref)	1 (0.79 , 1.27)	1.54 (1.2 , 1.96)	2.08 (1.56 , 2.79)	2.54 (1.86 , 3.46)	0.002
	23.9-28.6	0.9 (0.71 , 1.14)	1.13 (0.9 , 1.4)	1.13 (0.88 , 1.45)	1.41 (1.06 , 1.89)	1.75 (1.31 , 2.36)	
	28.7-33.5	1.12 (0.88 , 1.42)	1.09 (0.87 , 1.36)	1.2 (0.94 , 1.52)	1.74 (1.35 , 2.24)	1.93 (1.49 , 2.5)	
	33.6-39.2	1.36 (0.99 , 1.85)	1.37 (1.05 , 1.77)	1.43 (1.11 , 1.86)	1.6 (1.22 , 2.11)	1.57 (1.21 , 2.05)	
	39.3-69.8	2.14 (1.23 , 3.73)	1.15 (0.72 , 1.83)	1.3 (0.93 , 1.82)	1.55 (1.17 , 2.05)	1.87 (1.45 , 2.41)	
	Fatal/non-fatal CVD						
	HGS Quintile (kg)						
		43-90	35-42	29-34	23-28	0-22	P value for interaction
Fat mass quintile (%)	5-23.8	1 (ref)	0.98 (0.85 , 1.13)	1.05 (0.89 , 1.24)	1.05 (0.84 , 1.32)	1.06 (0.81 , 1.38)	0.333
	23.9-28.6	1.14 (0.99 , 1.31)	1.09 (0.95 , 1.25)	0.99 (0.84 , 1.16)	1.1 (0.9 , 1.34)	1.1 (0.89 , 1.36)	
	28.7-33.5	1.12 (0.97 , 1.31)	1.21 (1.05 , 1.39)	1.23 (1.06 , 1.43)	1.1 (0.92 , 1.31)	1.31 (1.1 , 1.56)	
	33.6-39.2	1.43 (1.17 , 1.74)	1.29 (1.08 , 1.53)	1.36 (1.15 , 1.61)	1.28 (1.07 , 1.53)	1.36 (1.15 , 1.61)	
	39.3-69.8	2.38 (1.66 , 3.42)	1.2 (0.89 , 1.63)	1.52 (1.25 , 1.85)	1.48 (1.24 , 1.76)	1.54 (1.31 , 1.81)	
	Fatal CVD						
	HGS Quintile (kg)						
		43-90	35-42	29-34	23-28	0-22	P value for interaction
Fat mass quintile (%)	5-23.8	1 (ref)	1.01 (0.7 , 1.46)	1.58 (1.08 , 2.31)	2.55 (1.66 , 3.9)	3.23 (2.06 , 5.08)	0.004
	23.9-28.6	0.78 (0.53 , 1.15)	1.3 (0.93 , 1.82)	1.29 (0.89 , 1.87)	1.59 (1.03 , 2.47)	1.91 (1.21 , 3.01)	
	28.7-33.5	1.23 (0.85 , 1.78)	1.24 (0.88 , 1.74)	1.19 (0.82 , 1.73)	1.88 (1.27 , 2.78)	2.3 (1.54 , 3.42)	
	33.6-39.2	1.68 (1.07 , 2.62)	1.73 (1.18 , 2.53)	1.93 (1.32 , 2.82)	2.03 (1.34 , 3.09)	1.88 (1.24 , 2.83)	
	39.3-69.8	2.5 (1.13 , 5.53)	1.2 (0.59 , 2.46)	1.81 (1.1 , 3)	1.78 (1.13 , 2.81)	2.17 (1.45 , 3.27)	

*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and deprivation HGS – hand grip strength


Table S14. Results of MR using continuous genetic risk scores with interaction between HGS and BMI/WHR.

	Outcome	HR per unit increase in HGS at the median BMI/WHR	HR per unit increase in BMI/WHR at the median HGS	Interaction term (HR)	Interaction p- value
WHR	Fatal/Non Fatal CVD	1.03 (0.97 , 1.08)	1.04 (1.00 , 1.07)	0.95 (0.87 , 1.03)	0.205
	CVD Mortality	0.88 (0.75 , 1.02)	0.99 (0.90 , 1.08)	0.92 (0.72 , 1.17)	0.478
	All-cause mortality	0.87 (0.80 , 0.94)	1.02 (0.96 , 1.07)	0.94 (0.82 , 1.07)	0.339

WHR – waist hip ratio, BMI – body mass index HGS – hand grip strength

Figure S1. Estimated association between body composition and fatal/non-fatal CHD and CVD events and cause specific and all-cause mortality excluding the first 2, 3 and 4 years of follow up: BMI and Hand Grip Strength.


BMI and Hand Grip Strength



Associations (adjusted* Hazard Ratios (HRs)) estimated from a Cox Proportional Hazards model, fit separately for those with and without baseline history of CVD. Reference category is optimal body composition, i.e. not sarcopenic and not obese. Obesity measured by BMI, and sarcopenia by dominant hand grip strength (HGS).


*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and deprivation

Figure S2. Estimated association between body composition and fatal/non- CHD events and mortality. Obesity measured as BMI > 30, sarcopenia measured as HGS<30kg men and <20kg women.




*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and deprivation

Figure S3. Estimated association between body composition and fatal/non- CVD events and cause specific and all-cause mortality. Obesity measured as BMI>30, sarcopenia measured as SMMI in bottom 40%.




*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and deprivation

Figure S4. Estimated association between body composition and fatal/non- CVD events and cause specific and all-cause mortality. Obesity measured as WHR ≥ 0.95 in men and ≥ 0.80 in women, sarcopenia measured as HGS < 30 kg men and < 20 kg women.



*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and deprivation

Figure S5. Relative hazard of fatal/non-fatal CHD and CVD events and cause specific and all-cause mortality according to category of body composition (using WHR) as defined by genetic scores in a factorial Mendelian randomisation analysis, where weights for the genetic score were determined from both external and internal data.



High/Low determined by cutting at the median genetic score. Associations (Hazard Ratios (HRs)) estimated from a Cox Proportional Hazards model. P value for the interaction calculated using a likelihood ratio test.

Figure S6. Relative hazard of fatal/non-fatal CHD events and mortality according to category of body composition as defined by genetic scores estimated from both external in internal weights in a factorial Mendelian randomisation analysis.

